MOMS Act
Summary
The MOMS Act (S.1630) is an early-stage bill referred to committee with no authorized funding amount. It creates a procedural requirement for HHS to build a pregnancy.gov website. There is no near-term market impact. Recent declines in $ACN and $IBM are driven by broader tech weakness, not this legislation.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.The MOMS Act is a procedural bill with zero authorized funding and no near-term market impact.
- 2.No public companies are directly affected; any potential IT contracting is purely hypothetical and immaterial.
- 3.Recent stock declines in $ACN and $IBM are driven by broad market tech weakness, not this legislation.
Market Implications
No market implications from this bill. Investors should watch broader tech sector trends for $ACN and $IBM performance. $ACN's 52-week low of $173.67 is nearby, while $IBM is already near its low of $220.72. The 30-day declines of -10.47% and -5.91% respectively reflect macro headwinds, not legislative catalysts.
Full Analysis
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Some confirming evidence found across public data sources
Market Impact Score
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
DELL FEDERAL SYSTEMS L.P: $602M Department of Veterans Affairs Contract
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $1.1B Department of Veterans Affairs Contract
American Innovation and R&D Competitiveness Act of 2025
Protecting Health Care and Lowering Costs Act of 2025
To amend the Export Control Reform Act of 2018 to provide for expedited consideration of proposals for additions to, removals from, or other modifications with respect to entities on the Entity List, and for other purposes.
ADVANCED TECHNOLOGY INTERNATIONAL: $304M Department of Health and Human Services Contract
Consolidated Appropriations Act, 2026
Stop Secret Spending Act of 2025
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.
Accelerating Medical Treatments for Serious Mental Illness
This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.